WB: Adding Atezolizumab to Cabozantinib Offers No Benefit in Advanced Renal Cancer

For patients with locally advanced or metastatic renal cell carcinoma with disease progression on or after immune checkpoint inhibitor treatment, the addition of atezolizumab to cabozantinib does not improve clinical outcomes, according to a study published in The Lancet to coincide with the ASCO annual meeting, held recently in Chicago. Sumanta Kumar Pal, MD, and colleagues conducted a randomized, open-label, phase 3 trial at 135 study sites in 15 countries involving patients with locally advanced or metastatic renal cell carcinoma whose disease had progressed with immune checkpoint inhibitors. Participants, aged 18 or older, were randomly assigned to atezolizumab plus cabozantinib or cabozantinib alone (263 and 259, respectively) from July 28, 2020, to December 27, 2021. At data cutoff, with a median follow-up of 15.2 months, 65% and 64% of patients receiving
atezolizumab- cabozantinib and cabozantinib, respectively, had disease progression per central review or died. The median progression-free survival was 10.6 and 10.8 months with atezolizumab-cabozantinib and cabozantinib, respectively.